In various animal model experiments, VCAM-1 blockade reduces the severity of inflammatory reaction in atopic dermatitis, multiple sclerosis, and Crohn’s disease, mostly by blocking T cell infiltration into the affected tissues [25,26]. Here, VCAM1 is linked to atopic eczema.